Back

AACR-NCI-EORTC 2019 - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 26 - Oct 30, 2019 | BostonMAUS

LARVOL is not affiliated with AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and all trademarks, logos, and brand names are property of their respective owners

Showing 54 abstracts linked to Trials

A003 - Anti-angiogenic activity of the CXCR4 antagonist balixafortide

  • Poster

A028 - Clinical and analytic validation of FoundationOne CDx&[trade] for NTRK fusion-positive solid tumors in patients treated with entrectinib

  • Poster

A029 - Biomarker analysis of patients with MET&[Delta]ex14 mutated non-small-cell lung cancer (NSCLC) treated with capmatinib in the GEOMETRY mono-1 study

  • Poster

A031 - Association of tumor DNA in circulation with clinical characteristics and treatment response in HR+/HER2&[minus] advanced breast cancer

  • Poster

A070 - A phase 1/2a, open-label, dose-escalation study of EC-18 in patients with metastatic breast cancer for the prevention of chemotherapy-induced neutropenia

  • Poster

A072 - Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma

  • Poster

A073 - Using prebaseline and on-treatment tumor assessments to compare time to tumor size progression of hormonal therapy + sapanisertib vs an extrapolated hormonal therapy alone from a single-arm phase 2 study

  • Poster

A074 - Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

  • Poster

A077 - FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations

  • Poster

A078 - FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies

  • Poster

A079 - National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies

  • Poster

A082 - A phase 1, first-in-human, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma

  • Poster